Global Patent Index - EP 2046325 A1

EP 2046325 A1 20090415 - PHYTOESTROGENIC FORMULATIONS AND USES THEREOF

Title (en)

PHYTOESTROGENIC FORMULATIONS AND USES THEREOF

Title (de)

PHYTOÖSTROGENFORMULIERUNGEN UND IHRE VERWENDUNG

Title (fr)

FORMULATIONS PHYTO- STROGÉNIQUES POUR SOULAGER OU PRÉVENIR DES MALADIES NEURODÉGÉNÉRATIVES

Publication

EP 2046325 A1 20090415 (EN)

Application

EP 07812924 A 20070713

Priority

  • US 2007073505 W 20070713
  • US 81984906 P 20060802
  • US 88992007 P 20070214
  • US 94319007 P 20070611

Abstract (en)

[origin: WO2008016768A1] Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological health and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERß over ERa and agonist activity in the brain. These ERß-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotection mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. The select phytoestrogen formulations are therapeutically useful to both women and men for sustaining neurological health and preventing age-related cognitive decline and neurodegenerative disorders, such as AD. These are administered enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer's Disease. The formulations preferably contain combinations of compounds, and can be formulated for daily, sustained, delayed or weekly/monthly administration. In a preferred embodiment, these are administered to women who are in menopause or post menopausal, most preferably early in menopausal.

IPC 8 full level

A61K 31/352 (2006.01); A61K 31/353 (2006.01); A61K 36/48 (2006.01); A61P 5/30 (2006.01)

CPC (source: EP)

A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 36/48 (2013.01); A61P 5/30 (2017.12); A61P 15/12 (2017.12); A61P 17/00 (2017.12); A61P 19/10 (2017.12); A61P 25/00 (2017.12); A61P 25/28 (2017.12); A61P 43/00 (2017.12)

Citation (search report)

See references of WO 2008016768A1

Citation (examination)

CHIECHI L M ET AL: "Utility of dietary phytoestrogens in preventing postmenopausal osteoporosis", CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, NEW CENTURY HEALTH PUBLISHERS, NEW ORLEANS, LA, US, vol. 3, no. 1, 1 January 2005 (2005-01-01), pages 15 - 28, XP001537660, ISSN: 1540-7535

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL BA HR MK RS

DOCDB simple family (publication)

WO 2008016768 A1 20080207; WO 2008016768 A8 20080612; AU 2007281381 A1 20080207; CA 2659905 A1 20080207; EP 2046325 A1 20090415; JP 2009545605 A 20091224

DOCDB simple family (application)

US 2007073505 W 20070713; AU 2007281381 A 20070713; CA 2659905 A 20070713; EP 07812924 A 20070713; JP 2009522917 A 20070713